Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of...
Reexamination Certificate
2011-04-05
2011-04-05
Cochrane Carlson, Karen (Department: 1656)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
C536S023100, C530S350000
Reexamination Certificate
active
07919313
ABSTRACT:
Disclosed herein are methods and compositions for inactivating a FUT8 gene, using fusion proteins comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding said fusion proteins are also provided, as are cells comprising said polynucleotides and fusion proteins.
REFERENCES:
patent: 5356802 (1994-10-01), Chandrasegaran
patent: 5436150 (1995-07-01), Chandrasegaran
patent: 5487994 (1996-01-01), Chandrasegaran
patent: 5789538 (1998-08-01), Rebar et al.
patent: 5925523 (1999-07-01), Dove et al.
patent: 6007988 (1999-12-01), Choo et al.
patent: 6013453 (2000-01-01), Choo et al.
patent: 6140081 (2000-10-01), Barbas
patent: 6140466 (2000-10-01), Barbas et al.
patent: 6200759 (2001-03-01), Dove et al.
patent: 6242568 (2001-06-01), Barbas et al.
patent: 6410248 (2002-06-01), Greisman et al.
patent: 6453242 (2002-09-01), Eisenberg et al.
patent: 6479626 (2002-11-01), Kim et al.
patent: 6503717 (2003-01-01), Case et al.
patent: 6534261 (2003-03-01), Cox et al.
patent: 6599692 (2003-07-01), Case et al.
patent: 6607882 (2003-08-01), Cox, III et al.
patent: 6689558 (2004-02-01), Case
patent: 6824978 (2004-11-01), Cox, III et al.
patent: 6903185 (2005-06-01), Kim et al.
patent: 6933113 (2005-08-01), Case et al.
patent: 6946292 (2005-09-01), Kanda et al.
patent: 6979539 (2005-12-01), Cox, III et al.
patent: 7013219 (2006-03-01), Case et al.
patent: 7153949 (2006-12-01), Kim et al.
patent: 7163824 (2007-01-01), Cox, III et al.
patent: 2003/0108880 (2003-06-01), Rebar et al.
patent: 2003/0232410 (2003-12-01), Liljedahl et al.
patent: 2005/0026157 (2005-02-01), Baltimore
patent: 2005/0064474 (2005-03-01), Urnov et al.
patent: 2005/0208489 (2005-09-01), Carroll
patent: 2006/0063231 (2006-03-01), Li et al.
patent: 2006/0188987 (2006-08-01), Guschan et al.
patent: 2007/0134796 (2007-06-01), Holmes et al.
patent: 2007/0218528 (2007-09-01), Miller
patent: 2008/0015164 (2008-01-01), Collingwood
patent: 2008/0131962 (2008-06-01), Miller
patent: 2338237 (1999-12-01), None
patent: WO 95/19431 (1995-07-01), None
patent: WO 96/06166 (1996-02-01), None
patent: WO 98/37186 (1998-08-01), None
patent: WO 98/53057 (1998-11-01), None
patent: WO 98/53058 (1998-11-01), None
patent: WO 98/53059 (1998-11-01), None
patent: WO 98/53060 (1998-11-01), None
patent: WO 98/54311 (1998-12-01), None
patent: WO 00/27878 (2000-05-01), None
patent: WO 01/60970 (2001-08-01), None
patent: WO 01/88197 (2001-11-01), None
patent: WO 02/16536 (2002-02-01), None
patent: WO 02/077227 (2002-10-01), None
patent: WO 02/099084 (2002-12-01), None
patent: WO 03/016496 (2003-02-01), None
patent: WO 2007/014275 (2007-01-01), None
Bae, et al., “One-Step Selection of Artificial Transcription Factors Using an in Vivo Screening System,”Molecules and Cells21:376-380 (2006).
Imai-Nishiya, et al., “Double Knockdown of A1,6-Fucosyltransferase (FUT8) and GDP-Mannose 4,6-Dehydratase (GMD) in Antibody-Producing Cells: A New Strategy for Generating Fully Non-Fucosylated Therapeutic Antibodies With Enhanced ADCC,”BMC Biotechnology7:84 (2007).
Kanda, et al., “Comparison of Cell Lines for Stable Production of Fucose-Negative Antibodies With Enhanced ADCC,”Biotechnology and Bioengineering94:680-688 (2006).
Meng, et al., “Profiling the DNA-Binding Specificities of Engineered CYS2HIS2 Zinc Finger Domains Using a Rapid Cell-Based Method,”Nucleic Acids Res35:e81 (2007).
Satoh, et al., “Non-Fucosylated Therapeutic Antibodies as Next-Generation Therapeutic Antibodies,”Expert Opin Biol Ther6:1161-1173 (2006).
Shinkawa, et al., “The Absence of Fucose But Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IGG1 Complex-Type Oligosaccharides Shows the Critical Role of Enhancing Antibody-Dependent Cellular Cytotoxicity,”JBC278:3466-3473 (2003).
Beerli, et al., “Engineering Polydactyl Zinc-Finger Transcription Factors,”Nature Biotechnology20:135-141 (2002).
Choo, et al., “Advances in Zinc Finger Engineering,”Curr. Opin. Struct. Biol. 10:411-416 (2000).
Goodarzi et al., “Decreased Branching, Increased Fucosylation and Changed Sialylation of Alpha-1-Proteinase Inhibitor in Breast and Ovarian Cancer,”Clin Chim Acta236(2): 161-171.
Isalan et al., “A Rapid, Generally Applicable Method to Engineer Zinc Fingers Illustrated by Targeting the HIV-1 Promoter,”Nat Biotechnol19:656-660 (2001).
Kanda, et al., “Establishment of a GDP-Mannose 4,6-Dehydratase (GMD) Knockout Host Cell Line: A New Strategy for Generating Completely Non-Fucosylated Recombinant Therapeutics,”J. Biotechnology130(3):300-310 (2007).
Kanda, et al., “Comparison of Biological Activity Among Nonfucosylated Therapeutic IGG1 Antibodies With Three Different N-Linked FC Oligosaccharides: The High-Mannose, Hybrid, and Complex Types,”Glycobiology17:104-118 (2006).
Kim, et al., “Chimeric Restriction Endonuclease,”PNAS USA91:883-887 (1994).
Kim, et al., “Insertion and Deletion Mutants of FOKI Restriction Endonuclease,”J. Biol. Chem. 269:31978-31981 (1994).
Li, et al., “Functional Domains in FOK I Restriction Endonuclease,”PNAS USA89:4275-4279 (1992).
Li, et al., “Alteration of the Cleavage Distance of FOK I Restriction Endonuclease by Insertion Mutagenesis,”PNAS USA90:2764-2768 (1993).
Mori, et al., “Engineering Chinese Hamster Ovary Cells to Maximize Effector Function of Produced Antibodies Using FUT8 Sirna,”Biotechnology Bioeng88:901-908 (2004).
Ohyama, et al., “Molecular Cloning and Expression of GDP-D-Mannose-4,6-Dehydratase, A Key Enzyme for Fucose Metabolism Defective in LEC13 Cells,”J Biol Chem273:14582-14587 (1998).
Oriol, et al., “Divergent evolution of Fucosyltransferase Genes From Vertebrates, Invertebrates, and Bacteria,”Glycobiology9:323-334 (1999).
Pabo, et al., “Design and Selection of Novel CYS2-HIS2 Zinc Finger Proteins,”Ann. Rev. Biochem. 70:313-340 (2001).
Ripka, et al., “Lectin-Resistant CHO Cells: Selection of Four New PEA Lectin-Resistant Phenotypes,”Somal Cell Mol Genet12:51-62 (1986).
Saitoh, et al., “Structural Analysis on the Sugar Chains of Human 1-Antitrypsin: Presence of Fucosylated Biantennary Glycan in Hepatocellular Carcinoma,” Archives Biochem & Biophysics 303:281-287 (1993).
Segal, et al., “Custom DNA-Binding Proteins Come of Age: Polydactyl Zinc-Finger Proteins,”Curr. Opin. Biotechnol. 12:632-637 (2001).
Thompson, et al., “Fucosypated Forms of Alpha-1-Antitrypsin That Predict Unresponsiveness to Chemoptheray in Ovarian Cancer,”Br J Cancer58(5):589-593 (1988).
Umov, et al., “Highly Efficient Endogenous Human Gene Correction Using Designed Zinc-Finger Nucleases,”Nature435:646-651 (2005).
Yamane-Ohnuki, et al., “Establishment of FUT8 Knockout Chinese Hamster Ovary Cells: An Ideal Host Cell Line for Producing Completely Defucosylated Antibodies With Enhanced Antibody-Dependent Cellular Cytotoxicity,”Biotechnol Bioeng87:614-622 (2004).
Collingwood Trevor
Cost Gregory J.
Carlson Karen Cochrane
Pasternak Dahna S.
Robins & Pasternak LLP
Sangamo Biosciences, Inc.
LandOfFree
Methods and compositions for inactivating alpha 1,6... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for inactivating alpha 1,6..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for inactivating alpha 1,6... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2639193